retatrutide mechanism gip glp-1 glucagon triple agonist Mounjaro: Retatrutide and Diabetes Retatrutide Mechanism of Action: Triple

An exciting development in the research surrounding semaglutide is that it can also benefit your heart health, its the first weight loss medication approved to cut heart disease risk by up to 20%*

Explore the full application note #Biopharma #LCMS #DrugDiscovery #Tirzepatide #GLP1 #Agilent To view or add a comment, sign in The GLP-1 Race Is No Longer About the Molecule Its About Delivery On January 12, 2026, Chinas CDE approved Shiling Pharmas Semaglutide Nasal Spray for clinical trials in long-term weight managementmarking the worlds first mucosal GLP-1 therapy (Class 2.2 innovation)

Bottom line With nearly 30% weight loss, substantial A1C reductions, and meaningful improvements across multiple obesity-related complications, Eli Lilly and Companys #retatrutide continues to emerge as one of the most closely watched next-generation metabolic therapies in development

Presented for research literature review only Hoffmann M et al